Table 4.
SARS-CoV-2 neutralizing antibody titers according to anticancer therapy.
| Strongly positive | Weakly positive | Serum negative | |
|---|---|---|---|
| All cancers | 28 (56%) | 15 (30%) | 7 (14%) |
| •Therapy in early BC setting | 7 (14%) | 5 (10%) | 7 (14%) |
| Anthracycline-based chemotherapy | 5 (10%) | 3 (6%) | 7 (14%) |
| Target therapy | 2 (4%) | 2 (4%) | 0 (0%) |
| •Therapy for advanced BC disease | 16 (32%) | 9 (18%) | 0 (0%) |
| Non-anthracycline-based chemotherapy | 5 (10%) | 4 (8%) | 0 (0%) |
| Target therapy | 11 (22%) | 5 (10%) | 0 (0% |
| * Therapy in early GC setting | 2 (4%) | 0 (0%) | 0 (0%) |
| * Non-anthracycline-based chemotherapy | 2 (4%) | 0 (0%) | 0 (0%) |
| * Therapy for advanced GC disease | 3 (6%) | 1 (2%) | 0 (0%) |
| Non-anthracycline-based chemotherapy | 1 (2%) | 1 (2%) | 0 (0%) |
| * Target therapy | 2 (4%) | 0 (0%) | 0 (0%) |
BC, breast cancer; GC, gynecological cancer.